# Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

> **NCT04304352** · PHASE2 · UNKNOWN · sponsor: **European Institute of Oncology** · enrollment: 162 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Capecitabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04304352
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07-29
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04304352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04304352, "Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04304352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*